| Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancer C Liu, W Lou, Y Zhu, N Nadiminty, CT Schwartz, CP Evans, AC Gao Clinical cancer research 20 (12), 3198-3210, 2014 | 359 | 2014 |
| Intracrine androgens and AKR1C3 activation confer resistance to enzalutamide in prostate cancer C Liu, W Lou, Y Zhu, JC Yang, N Nadiminty, NW Gaikwad, CP Evans, ... Cancer research 75 (7), 1413-1422, 2015 | 260 | 2015 |
| NF-κB2/p52 induces resistance to enzalutamide in prostate cancer: role of androgen receptor and its variants N Nadiminty, R Tummala, C Liu, J Yang, W Lou, CP Evans, AC Gao Molecular cancer therapeutics 12 (8), 1629-1637, 2013 | 214 | 2013 |
| Functional p53 determines docetaxel sensitivity in prostate cancer cells C Liu, Y Zhu, W Lou, N Nadiminty, X Chen, Q Zhou, XB Shi, ... The Prostate 73 (4), 418-427, 2013 | 145 | 2013 |
| Inhibition of ABCB1 expression overcomes acquired docetaxel resistance in prostate cancer Y Zhu, C Liu, N Nadiminty, W Lou, R Tummala, CP Evans, AC Gao Molecular cancer therapeutics 12 (9), 1829-1836, 2013 | 135 | 2013 |
| Inhibition of AKR1C3 activation overcomes resistance to abiraterone in advanced prostate cancer C Liu, CM Armstrong, W Lou, A Lombard, CP Evans, AC Gao Molecular cancer therapeutics 16 (1), 35-44, 2017 | 124 | 2017 |
| NF-κB2/p52: c-Myc: hnRNPA1 pathway regulates expression of androgen receptor splice variants and enzalutamide sensitivity in prostate cancer N Nadiminty, R Tummala, C Liu, W Lou, CP Evans, AC Gao Molecular cancer therapeutics 14 (8), 1884-1895, 2015 | 123 | 2015 |
| Inhibition of constitutively active Stat3 reverses enzalutamide resistance in LNCaP derivative prostate cancer cells C Liu, Y Zhu, W Lou, Y Cui, CP Evans, AC Gao The Prostate 74 (2), 201-209, 2014 | 115 | 2014 |
| Niclosamide suppresses cell migration and invasion in enzalutamide resistant prostate cancer cells via Stat3‐AR axis inhibition C Liu, W Lou, C Armstrong, Y Zhu, CP Evans, AC Gao The Prostate 75 (13), 1341-1353, 2015 | 114 | 2015 |
| Andrographolide, an herbal medicine, inhibits interleukin-6 expression and suppresses prostate cancer cell growth JY Chun, R Tummala, N Nadiminty, W Lou, C Liu, J Yang, CP Evans, ... Genes & cancer 1 (8), 868-876, 2010 | 112 | 2010 |
| Niclosamide enhances abiraterone treatment via inhibition of androgen receptor variants in castration resistant prostate cancer C Liu, C Armstrong, Y Zhu, W Lou, AC Gao Oncotarget 7 (22), 32210, 2016 | 108 | 2016 |
| Dietary sugar consumption and health: umbrella review Y Huang, Z Chen, B Chen, J Li, X Yuan, J Li, W Wang, T Dai, H Chen, ... Bmj 381, 2023 | 104 | 2023 |
| Inhibition of Stat3 activation by sanguinarine suppresses prostate cancer cell growth and invasion M Sun, C Liu, N Nadiminty, W Lou, Y Zhu, J Yang, CP Evans, Q Zhou, ... The Prostate 72 (1), 82-89, 2012 | 99 | 2012 |
| Proteostasis by STUB1/HSP70 complex controls sensitivity to androgen receptor targeted therapy in advanced prostate cancer C Liu, W Lou, JC Yang, L Liu, CM Armstrong, AP Lombard, R Zhao, ... Nature communications 9 (1), 4700, 2018 | 89 | 2018 |
| Interleukin‐6 induces neuroendocrine differentiation (NED) through suppression of RE‐1 silencing transcription factor (REST) Y Zhu, C Liu, Y Cui, N Nadiminty, W Lou, AC Gao The Prostate 74 (11), 1086-1094, 2014 | 79 | 2014 |
| ABCB1 mediates cabazitaxel–docetaxel cross-resistance in advanced prostate cancer AP Lombard, C Liu, CM Armstrong, V Cucchiara, X Gu, W Lou, CP Evans, ... Molecular cancer therapeutics 16 (10), 2257-2266, 2017 | 72 | 2017 |
| Antiandrogens inhibit ABCB1 efflux and ATPase activity and reverse docetaxel resistance in advanced prostate cancer Y Zhu, C Liu, C Armstrong, W Lou, A Sandher, AC Gao Clinical Cancer Research 21 (18), 4133-4142, 2015 | 67 | 2015 |
| AKR1C3 promotes AR-V7 protein stabilization and confers resistance to AR-targeted therapies in advanced prostate cancer C Liu, JC Yang, CM Armstrong, W Lou, L Liu, X Qiu, B Zou, AP Lombard, ... Molecular cancer therapeutics 18 (10), 1875-1886, 2019 | 63 | 2019 |
| Cross-resistance among next-generation antiandrogen drugs through the AKR1C3/AR-V7 axis in advanced prostate cancer J Zhao, S Ning, W Lou, JC Yang, CM Armstrong, AP Lombard, ... Molecular cancer therapeutics 19 (8), 1708-1718, 2020 | 56 | 2020 |
| Niclosamide and bicalutamide combination treatment overcomes enzalutamide-and bicalutamide-resistant prostate cancer C Liu, CM Armstrong, W Lou, AP Lombard, V Cucchiara, X Gu, JC Yang, ... Molecular cancer therapeutics 16 (8), 1521-1530, 2017 | 55 | 2017 |
Yezi ZhuUniversity of Texas, Austin在 austin.utexas.edu 的电子邮件经过验证
